EAST LYME, Conn.--(BUSINESS WIRE)--Phesi, a technology-enabled, data-driven provider of premier clinical development services, today announced the addition of Paul Chew, MD, as its Chief Medical Officer (CMO). Dr. Chew also joins the Phesi Board of Directors, which was expanded in 2017 by the appointments of Annalisa Jenkins, MBBS, FRCP, and Steve Arlington, PhD. Phesi leverages the industry’s most comprehensive clinical trials database and predictive analytics tools to help trial sponsors make timely and informed decisions, and to expedite drug development. Dr. Chew and the distinguished Board will help guide the company as it continues to expand its work with global life sciences companies.
“I am thrilled to have Dr. Chew join our growing team as we seek to enhance industry use of our unique clinical development platform,” said Gen Li, PhD, MBA, founder and president of Phesi. “His guidance, along with that of our other Board members, will help Phesi optimize our service offerings, which are designed to enable researchers to complete clinical trials on time and within budget.”
“Phesi is the pharmaceutical industry’s best-kept secret in that its rigorous scientific approach enhances the efficiency and cost-effectiveness of clinical trials, which currently take too long and are too expensive,” said Dr. Chew. “Phesi applies knowledge derived from observation and experimentation to inform new clinical programs or rescue ongoing ones, integrating all the moving pieces from early development planning through to Phase III, making Phesi a game-changer in the life sciences space.”
Over his distinguished career, Dr. Chew, a cardiologist by training, has held several executive positions at major pharmaceutical companies including Bristol-Myers Squibb and Sanofi, where he served as senior vice-president, global chief medical officer, and U.S. R&D head. He was most recently the CMO of Omada Health, where he and his team launched the largest randomized clinical trial to date in digital therapeutics. Dr. Chew serves as Medical Trustee on the U.S. Pharmacopeia Board of Trustees. He spent more than 20 years at the Johns Hopkins University and School of Medicine, where he received his undergraduate education, and medical training, and where he held various faculty positions.
Phesi’s granular and dynamic clinical trials database contains more information and records than any other source, including clinicaltrials.gov. Using proprietary methods, Phesi mines its database to consolidate real-time information from millions of data points to reduce trial start-up time, lower costs, minimize the number of protocol amendments, determine the appropriate number of trial sites, and accelerate time to launch. Phesi’s unique drug development technology platform can cut clinical trial design analysis timelines from 18-24 months to just 3-4 weeks, and reduce trial costs by 20%-40%.
Despite increasingly high societal demand to accelerate drug development and approval timelines, clinical trials are still largely managed by “old school” approaches, and therefore remain challenged by significant delays, ballooning costs, and irreproducible outcomes. According to the Tufts Center for the Study of Drug Development, the cost of bringing just one drug to market currently exceeds $2.5 billion.
Phesi offers smart technology with simple solutions for complex issues, removing common barriers to effective clinical trials and placing novel therapies into the hands of patients faster. Now in its 11th year in business, Phesi recently completed full automation of all of its systems, as well as a complete re-branding with a fresh, new logo and an updated website: www.phesi.com.
More About Phesi
Founded in 2007 as Pharmaceutical Pipeline Enhancement Strategies, Phesi is a dynamic, data-driven drug development company, providing comprehensive clinical development services for life sciences companies around the world. Phesi’s integrated service offerings cover the entire clinical development process: from development planning and indication assessment to protocol evaluation, site selection, and trial implementation management.
Phesi has the industry’s most comprehensive and dynamic clinical trials database and predictive analytics tools, consisting of more than 213,000 completed clinical trials, 604,000 completed clinical research projects, and over 1.6 million investigator records.
The leadership team at Phesi is driving the future of pharmaceutical R&D, offering unique perspectives on the optimal role of digital technology, the importance of building service organizations around new technology, and an overall understanding of the transformation that needs to happen to improve clinical development.
For more information please visit www.phesi.com. Follow Phesi on LinkedIn and Twitter.
